Tessera Therapeutics Stock
Tessera Therapeutics is an innovative life sciences company focused on pioneering a new biotechnology called Gene Writing™, which aims to revolutionize genetic medicine. Tessera is developing technologies that allow for precise and efficient modifications to the genome, addressing genetic diseases that traditional gene therapy and editing methods cannot effectively treat.
Sign up for SecondMarket™ to view the market and buy or sell Tessera Therapeutics Stock
Buy + SellTessera Therapeutics Funding
Sign up to gain insights into Tessera Therapeutics funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the DataDate | Financing Round | Amount | Price per share* | Valuation* |
---|---|---|---|---|
Mar 08, 2022 | Series C | 400.00M | ||
Jan 13, 2021 | Series B | 231.50M | ||
Jan 13, 2021 | Series A | 5.00M | ||
Sep 29, 2020 | Series A | 6.60M | ||
Sep 30, 2019 | Series A | 13.81M |
See Tessera Therapeutics Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Tessera Therapeutics Stock Valuation + Share Prices
View real-time Tape D™ data on Tessera Therapeutics stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get StartedTessera Therapeutics Management Team
Chief Data Officer
Ian McFayden
Chief Medical and Development Officer
David Davidson
Director
Mary Rozenman
Chief Operating Officer
Hari Pujar
Co-founder, Chief Innovation Officer
Jake Rubens
Director
Elliott Sigal
Chief Human Resources Officer
Becky Lillie
Chief Scientific Officer
Michael Holmes
CTO, Cell Therapy
Madhusudan Peshwa
CFO, President
Howard Liang
CEO, Director
Michael Severino
Director
Melissa Moore
Co-founder, Board Chair
Geoffrey von Maltzahn
Director
Noubar Afeyan
Tessera Therapeutics Major Investors
Qatar Investment Authority (QIA)
March Capital
Cormorant Asset Management
Hanwha Venture Capital Corporation
Alaska Permanent Fund (APFC)
Abu Dhabi Investment Authority (ADIA)
Artis Ventures
Longevity Fund, The
Longevity Fund, The
Softbank Vision Fund 2
Altitude Life Science Ventures
Flagship Pioneering